Sangamo Therapeutics, Inc. (SGMO) Financials

SGMO Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 60.0 million 78.9 million
Dec. 31, 2025 59.7 million 74.0 million
Sept. 30, 2025 88.6 million 82.4 million
June 30, 2025 97.6 million 78.0 million

SGMO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -19.3 million 992000
Dec. 31, 2025 -24.4 million 2.1 million
Sept. 30, 2025 -28.6 million 2.1 million
June 30, 2025 -18.2 million 2.2 million

SGMO Net Income

No data available :(

SGMO Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 27.6 million 19.3 million 19.3 million
Dec. 31, 2025 20.9 million - 26.8 million
Sept. 30, 2025 30.5 million - 25.4 million
June 30, 2025 38.3 million - 23.5 million

SGMO Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 389.6 million
Dec. 31, 2025 337.7 million
Sept. 30, 2025 304.3 million
June 30, 2025 257.0 million

SGMO Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 13000 26.6 million 6.8 million -
Dec. 31, 2025 14000 31.4 million 7.8 million -
Sept. 30, 2025 64000 28.1 million 8.0 million -
June 30, 2025 24000 27.1 million 9.1 million -

SGMO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 1.4 million -
Dec. 31, 2025 14.2 million 1.9 million
Sept. 30, 2025 581000 1.9 million
June 30, 2025 18.3 million -

SGMO Revenue by Segment
Graph available only for paid members. Upgrade to see it.

SGMO

Price: $0.22

52 week price:
0.10
0.77

Earnings Per Share: -0.40 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 882100

Ebitda: -12.6 million

Market Capitalization: 91.1 million

Links: